Abstract. Serum assays of NY-ESO-1 antibodies provide a guide to discriminate between patients who suffer from different types of cancer. In the present study, the expression of NY-ESO-1 was detected with the aim to identify a novel tumor antigen in colorectal cancer (CRC). Sera were obtained from 89 healthy individuals and 236 patients with CRC with stage I, II, III and IV tumors. The NY-ESO-1 autoantibody levels were determined using an enzyme-linked immunosorbent assay. The mRNA and protein expression levels of NY-ESO-1 were detected using reverse transcription-polymerase chain reaction and immunohistochemistry, respectively, in 60 CRC and paired adjacent non-tumor tissues. NY-ESO-1 antibody was detected in 40 of the 236 (16.9%) patients with CRC. The NY-ESO-1 antibody combined with carcinoembryonic antigen enhanced the sensitivity, from 52.1 to 62.7%, of the diagnosis of CRC. The frequency of antibody positivity increased with the TNM cancer stage (8.8 vs. 28.3% in stages I+II and III+IV, respectively). The mRNA and protein expression levels of NY-ESO-1 were significantly higher in CRC tissue than in adjacent non-tumor tissue. In conclusion, NY-ESO-1 is frequently expressed in CRC with the capacity of inducing a humoral immune response in CRC patients, exhibiting the potential to be a promising biomarker for CRC.
Introduction
Colorectal cancer (CRC) is one of the most common types of cancer in the world (1) . The prognosis of CRC depends on the stage at diagnosis, thus early detection of CRC has great potential to reduce the mortality of the disease (2) . It is of critical importance to improve the understanding of the pathogenesis of CRC, as well as to identify reliable biomarkers for CRC diagnosis and prognosis. The detection of serological biomarkers is used for CRC screening as it is convenient and relatively non-invasive; however, the effective clinical application of the majority of blood biomarkers is impeded by low detection sensitivity (3) . For example, carcinoem bryonic antigen (CEA) is widely accepted as a blood biomarker associated with CRC; however, the overall sensitivity for CEA detection in CRC varies between 43 and 69% (4) .
Cancer testis (CT) antigens are a group of tumor antigens that may elicit the immune system during tumorigenesis. One of the most common characteristics of CT antigens is their aberrant expression in multiple tumors and their absence in normal tissues, apart from in the testes and ovaries. As one of the most important CT antigens, NY-ESO-1 has attracted considerable attention due to the marked cellular and humoral immune responses it induces (5) . NY-ESO-1 autoantibody is often detected in patients with NY-ESO-1-positive esophageal (6), lung (7, 8) , breast (9), gastric (10) and hepatocellular (11) cancer. Therefore, NY-ESO-1 may be a valuable serological biomarker and provide a specific immunotherapeutic method for these types of cancer.
It is currently understood that NY-ESO-1-specific antibodies are more highly expressed in the advanced stages of CRC (12) ; however, knowledge about the expression of NY-ESO-1 in the CRC tissues, and the serological expression in early CRC, is lacking. The present study aimed to evaluate the mRNA and protein expression levels of NY-ESO-1 in CRC tissues, and the levels of NY-ESO-1 autoantibody in CRC patients according to the tumor stage.
Materials and methods
Ethics statement. The experimental protocols of the present study were approved by the Ethics Committee of Zhengzhou University (Zhengzhou, China). Written informed consent was provided by all participants. 
Reverse transcription-polymerase chain reaction (RT-PCR).
RNA was extracted from frozen CRC and adjacent non-tumor tissue using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Total RNA was reverse transcribed by using a reverse transcription system kit (cat. no. A3500; Promega Corp., Madison, WI, USA) according to the manufacture's protocol. The PCR primers were designed using Primer 5.0 design software (Primer Biosoft, Palo Alto, CA, USA). The sequences of the primers used were as follows: 5'-AGA CGT CGT AGG TAA GTC GGG AC-3' and 5'-GGA GGG AGT CCC GTC TCC GCG-3' for NY-ESO-1, and 5'-ACC ACA GTC CAT GCC ATC AC-3' and 5'-TCC ACC ACC CTG TTG CTG TA-3' for GAPDH. DNase was used to remove genomic DNA. Products were amplified by PCR using a Taq 2X PCR Master Mix (cat. no. KT201; Tiangen Biotech Co., Ltd., Beijing, China). A 25 µl reaction containing template (1 µl), primer (2 µl), Taq 2X PCR Master Mix (12.5 µl) and double-distilled H 2 O was produced and PCR was performed under the following conditions: Initial denaturation at 94˚C for 3 min, followed by 30 cycles of 94˚C for 30 sec, 60˚C for 45 sec and 72˚C for 45 sec, and a final extension step of 72˚C for 5 min. The size and quantity of the PCR products were verified by electrophoresis on 1.5% agarose gel stained with ethidium bromide. Relative mRNA expression levels were evaluated using the band intensity ratio of the target gene to GADPH. All PCR reactions were performed in triplicate. Densitometric analysis was performed using Tanon Image software 2500 (Tanon Science and Technology Co., Ltd., Shanghai, China). 
Immunohistochemistry (IHC

Results
Antibody response to NY-ESO-1 combined with CEA.
A total of 236 CRC patient sera and 89 healthy control sera were tested with ELISA to detect NY-ESO-1 humoral immune response positivity. In the control subjects, the mean OD value was 0.312, with a standard deviation (SD) of 0.147. The mean OD + 3 SD of the healthy control sera was used as the cut-off point for positivity for NY-ESO-1 antibodies. Consequently, the NY-ESO-1 response positivity was defined as an OD value of >0.75. The prevalence of antibodies against NY-ESO-1 was 16.9% in patients with CRC (40 of 236), compared with 2.2% in healthy control subjects (2 of 89). The relationship between antibodies against NY-ESO-1 and CEA was also investigated. In the CRC patients, 52.1% (123 of 236) were positive for CEA. The sensitivity of CRC diagnosis was significantly increased to 62.7% (148 of 236) following the combined detection of antibodies against NY-ESO-1 and CEA compared with CEA only (P=0.020) and NY-ESO-1 only (P<0.001; Fig. 1 ).
Correlation between antibodies against NY-ESO-1 and the clinicopathological parameters in CRC.
The potential correlation between NY-ESO-1 antibody expression and the clinicopathological parameters in CRC was investigated (Table I) . It was demonstrated that the NY-ESO-1 antibody positivity was significantly correlated with tumor progression, such as depth of tumor invasion, lymph node and distant metastasis (P=0.001, P<0.001 and P=0.03, respectively; Table I ). However, NY-ESO-1 antibody positivity demonstrated no significant correlation with sex, age, location and histological type. The correlation between NY-ESO-1 antibody positivity and tumor stage is demonstrated in Fig. 2 . The positive rates of antibodies against NY-ESO-1 in CRC patients increased from 6.3% in stage I tumors to 11, 23.1 and 34% in stage II, III and IV tumors, respectively.
NY-ESO-1 mRNA expression levels.
The expression level of NY-ESO-1 mRNA in CRC patients was analyzed using RT-PCR. NY-ESO-1 mRNA expression was detected in 21.7% (13 of 60) tumor specimens. No NY-ESO-1 mRNA was detected in the 60 adjacent non-tumor tissues (Fig. 3) .
Immunohistochemical staining. NY-ESO-1 protein was expressed in cancer cells; however, it was not expressed in adjacent non-tumor tissues. NY-ESO-1 protein was detected in 26.7% (16 of 60) of CRC patients and was located in the cytoplasm of cancer cells (Fig. 4) .
Discussion
Based on the fact that CT antigens are able to elicit cellular as well as humoral immune responses, it is understood that cancer cells may be recognized and killed by the immune Figure 3 . NY-ESO-1 mRNA expression levels in CRC tissues, as determined by reverse transcription-polymerase chain reaction. GADPH was used as an internal control. T, CRC tissue; N, paired adjacent non-tumor tissue; P, positive control (testis); Ne, negative control (no cDNA). system (14) . CT gene products represent attractive targets for cancer immunotherapy, and they are believed to be a promising therapeutic candidate for the treatment of many tumor types. One of the major barriers to antigen-specific immunotherapy in CRC is the lack of definite immunogenic tumor antigens. There is an urgent requirement for the identification of new targets for immunotherapy for CRC. NY-ESO-1 is a classic CT antigen, which was discovered during a SEREX analysis of esophageal cancer (15) . The expression of NY-ESO-1 antibody has been reported in a wide variety of cancer types; however, it has not been detected in normal tissue (16) (17) (18) . Therefore, NY-ESO-1 antibody represents an ideal target for antigen-specific immunotherapy. Furthermore, due to the expression characteristics of NY-ESO-1, it is considered to be a potential diagnostic marker for various cancer types (10, 19) .
The present study detected NY-ESO-1 antibody in 16.9% of CRC sera. This was not consistent with previous reports (20, 12) . These differences may have been caused by the sample size and the different cancer stage of patients. Furthermore, in the present study, the combination of NY-ESO-1 and CEA antibodies as tumor markers increased the rate of tumor detection from 52.1 to 62.7%. The measurement of CEA levels is commonly used to assess the prognosis of CRC patients. The expression of NY-ESO-1 is restricted to tumor tissues and NY-ESO-1 antibody is only detectable in patients with NY-ESO-1-expressing tumors (21) . Due to the highly specific expression of NY-ESO-1, the detection of NY-ESO-1 antibody may be used for diagnosing malignancy. From the present study, it may be considered that NY-ESO-1 antibody has potential clinical application as a novel biomarker in combination with CEA for CRC detection.
Due to NY-ESO-1 antibody being expressed in CRC, the present study investigated the possible relationship between NY-ESO-1 antibody expression and the clinicopathological parameters of CRC. Results suggested that NY-ESO-1 antibody expression was significantly correlated with depth of tumor invasion, lymph node metastasis and distant metastasis in CRC, irrespective of age, sex, location and histological type. The positive rates of serum NY-ESO-1 antibodies in patients with CRC gradually increased according to the tumor stage. NY-ESO-1 antibody expression had a higher frequency in TNM stage III and IV tumors (28.3%) than in stage I and II tumors (8.8%). TNM stage is one of the most essential prognostic factors in CRC (22, 23) . The critical correlation between NY-ESO-1 antibody expression and TNM stage may indicate that NY-ESO-1 antibody expression is a poor prognostic factor. In contrast, due to the antibody and T cell responses induced in CRC (20, 12) , NY-ESO-1 antibody expression may favor the prognosis of the patients with advanced TNM stages. Therefore, the relationship between NY-ESO-1 antibody expression and prognosis remains unclear and additional investigation is required to increase the understanding of this relationship.
In the present study, a higher number of NY-ESO-1-positive tissue was detected by IHC than by RT-PCR (16 vs. 13 out of 60, respectively). The inconsistency between tissue and serum antibody expression may be attributed to the limited number of tumor specimens. Extensive RT-PCR and IHC analysis should be employed to analyze the relationship between NY-ESO-1 expression levels and the clinicopathological parameters of CRC.
In conclusion, the present study demonstrated that NY-ESO-1 and NY-ESO-1 antibody are expressed in patients with CRC. Therefore, NY-ESO-1, as with other important CT antigens, may be used as a serum biomarker in combination with other conventional serum tumor markers in CRC diagnosis. The association between NY-ESO-1 antibody and immunogenicity means that the NY-ESO-1 antibody may be used as an alternative biomarker for vaccine treatments in subsequent research.
